Prevacid follow-up to move into Phase III trials

Share this article:
Japan's Takeda Pharmaceutical said today that a successor to its blockbuster anti-ulcer drug Prevacid would move into Phase III trials in the U.S.
A spokesman for Takeda told Reuters the FDA had allowed the company to skip Phase II clinical trials of the compound, known as TAK-390MR, because its molecular structure is a mirror image of Prevacid.
"Phase I clinical trial data have shown that TAK-390MR may have the potential to bring additional benefits to patients who suffer from acid-related diseases," said Francois-Xavier Frapaise, vice president of research and development for TAP Pharmaceutical Products, the joint venture between Takeda and Abbott Laboratories which, pending approval, would market the compound in the U.S. "We are enthusiastic to initiate a comprehensive Phase III clinical program involving more than 5,000 patients."
Takeda's president Yasuchika Hasegawa first revealed TAK-390MR earlier this month. Hasegawa said in published reports that the company aimed to release the drug in 2008.
Analysts are closely eyeing development of TAK-390MR. The compound's success could help cushion the huge losses expected for Takeda's profits when Prevacid's patent expires in 2009.
Global sales of Prevacid reached $3.4 billion last year – 37 percent of Takeda's total sales
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.